Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 19/20 | 0.58 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.58 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14313626 | 0.85 | PTGER1 (0.61) | PTGER1PTGER3TBXA2RSMN1; SMN2 | |
| SCHEMBL4522818 | 0.85 | PTGER1 (0.60) | PTGER1PTGER3TBXA2RSMN1; SMN2 | |
| SCHEMBL4520918 | 0.84 | PTGER1 (0.66) | PTGER1PTGER3TBXA2R | |
| SCHEMBL4537847 | 0.83 | PTGER1 (0.58) | PTGER1PTGER3TBXA2RSMN1; SMN2 | |
| SCHEMBL4162917 | 0.83 | PTGER1 (0.60) | PTGER1PTGER3TBXA2R | |
| SCHEMBL3929525 | 0.81 | PTGER1 (0.56) | PTGER1PTGER3TBXA2RSMN1; SMN2 | |
| SCHEMBL4522422 | 0.80 | PTGER1 (0.61) | PTGER1PTGER3TBXA2R | |
| SCHEMBL13602648 | 0.79 | PTGER1 (0.61) | PTGER1PTGER3TBXA2R | |
| SCHEMBL4515123 | 0.79 | PTGER1 (0.61) | PTGER1PTGER3TBXA2R | |
| SCHEMBL3180223 | 0.75 | PTGER1 (0.81) | PTGER1PTGER3TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298866-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| US-20090298866-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| US-20090298866-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| EP-2044062-A1 | INDOLE COMPOUNDS | Glaxo Group Limited (GB) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008006793-A1 | INDOLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008006793-A1 | INDOLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298866-A1 | Indole Compounds | IDO1, TPH1, IDO2 | PTGER1 317/4885PTGER3 361/4885TBXA2R 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.